Openai and FDA are said to discuss artificial intelligence to assess a drug

Openai met with officials from the US Food and Drug Administration (FDA) to discuss the agency’s use of artificial intelligence to accelerate drug reviews, I mentioned wireless Wednesday.

According to the report, Openai and FDA discussed a project called CderGPT, which appears to be the Amnesty International for the CDE. Oncent prescription CDE organizes a prescription in US partners from Elon Musk’s Doge as well.

It is not uncommon for drug development processes to take more than a decade. Openai’s work with FDA aims to accelerate a small part of this timeline, at the end, for every wireless. Artificial intelligence has long been described as a potential speed that can be used during the development of the drugWhich makes some slow steps more efficient. However, there are unanswered questions about how to control the lack of reliability of artificial intelligence models.